POMC and depressive symptom measurement: An enhanced secretion of corticotropin-releasing factor (CRF) and adrenocorticotropic hormone (ACTH), and decreased cortisol levels were observed during the withdrawal period in humans and linked to depression and anxiety symptoms [60, 61].